Bayer shares surged on Monday after the company reported encouraging late-stage clinical trial results for its experimental cardiovascular drug asundexian, offering a rare boost for a pharmaceutical division that has struggled with setbacks and mounting litigation costs. The stock rose more than 9% and traded at €30.30—its highest level in…
Google Cloud has confirmed a new multi-million dollar contract with the NATO Communication and Information Agency to deliver a…
This sharp contraction in overseas shipments has been attributed by industry officials and analysts primarily to the implementation of…
Saudi Aramco is exploring a sweeping round of asset sales that could reshape how the company manages its vast…
On Monday, investors urged BHP to drop its pursuit of Anglo American and instead focus on its established growth…
Oracle stock price has suffered a major reversal as concerns about the artificial intelligence (AI) and its soaring debt…
Zoom stock price has remained in a deep consolidation phase in the past few years as demand for its…
Tesla is moving closer to completing the design of its next-generation AI5 chip and has already begun development work…
JPMorgan’s senior analyst Kian Abouhossein has outlined his preferred European bank stocks as investors look ahead to 2026.Despite macroeconomic…